KALA BIO, Inc. (NASDAQ: KALA) announced the implementation of a 1-for-50 reverse stock split of its common stock, effective at 4:05 p.m. on May 8, 2026. The split-adjusted shares are set to begin trading on the Nasdaq Capital Market at the open on May 11, 2026, under the same ticker symbol 'KALA'. This corporate action reduces the company’s outstanding common shares from approximately 929.5 million to 18.6 million, a significant consolidation aimed at meeting Nasdaq’s minimum bid price requirement.
The reverse stock split is a strategic move by KALA BIO, a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company’s dual strategy combines a proprietary biologics pipeline—including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug- and Fast Track-designated product candidates—with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI solutions directly within biotech and pharmaceutical client environments.
Under the terms of the reverse split, proportional adjustments will be made to outstanding equity awards, warrants, and other convertible securities, and cash payments will be issued in lieu of fractional shares. This consolidation is a common tactic for companies facing delisting risks, as it mechanically boosts the stock price. For KALA BIO, the move is critical to maintain its listing on the Nasdaq Capital Market, ensuring continued access to public capital markets and investor visibility.
The importance of this reverse stock split extends beyond mere compliance. KALA BIO is positioning itself as a key player in the life sciences AI sector through its exclusive worldwide license for the Researgency AI research platform from Younet. The company intends to serve as the dedicated AI infrastructure partner for the biotechnology industry, enabling organizations of all sizes to unlock the value of their proprietary biological data without surrendering control. By advancing an agentic transformation strategy through Researgency.ai, KALA aims to enable scalable, governed deployment of AI agents across research, documentation, and operational workflows.
For investors and industry observers, the reverse stock split signals KALA BIO’s commitment to its long-term strategy despite near-term stock price challenges. The company’s focus on enterprise security, real-time performance, and seamless integration positions it at the forefront of innovation in the life sciences AI sector. However, reverse splits can sometimes be viewed as a red flag, potentially indicating financial distress. In KALA’s case, the move is a proactive step to stabilize its stock and attract institutional investors who may have been unable to invest due to the low share price.
The impact on shareholders is immediate: the number of shares held will be divided by 50, while the stock price will increase proportionally. Fractional shareholders will receive cash payments. The company’s market capitalization remains unchanged, but the higher per-share price could improve liquidity and reduce trading volatility. For the broader biotech industry, KALA’s reverse split highlights the challenges faced by clinical-stage companies with large share counts, often a result of multiple fundraising rounds.
KALA BIO, Inc. is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The company’s dual strategy combines a proprietary biologics pipeline with a scalable AI platform-as-a-service business. For more information about the company, please visit https://www.researgency.ai/.
To view the full press release, visit https://ibn.fm/yUznR.
